[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AU2001276619A1 - Immunisation against chlamydia pneumoniae - Google Patents

Immunisation against chlamydia pneumoniae

Info

Publication number
AU2001276619A1
AU2001276619A1 AU2001276619A AU7661901A AU2001276619A1 AU 2001276619 A1 AU2001276619 A1 AU 2001276619A1 AU 2001276619 A AU2001276619 A AU 2001276619A AU 7661901 A AU7661901 A AU 7661901A AU 2001276619 A1 AU2001276619 A1 AU 2001276619A1
Authority
AU
Australia
Prior art keywords
chlamydia pneumoniae
against chlamydia
immunisation against
immunisation
pneumoniae
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001276619A
Inventor
Guido Grandi
Giulio Ratti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GSK Vaccines SRL
Original Assignee
Chiron SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0016363A external-priority patent/GB0016363D0/en
Priority claimed from GB0017047A external-priority patent/GB0017047D0/en
Priority claimed from GB0017983A external-priority patent/GB0017983D0/en
Priority claimed from GB0019368A external-priority patent/GB0019368D0/en
Priority claimed from GB0020440A external-priority patent/GB0020440D0/en
Priority claimed from GB0022583A external-priority patent/GB0022583D0/en
Priority claimed from GB0027549A external-priority patent/GB0027549D0/en
Priority claimed from GB0031706A external-priority patent/GB0031706D0/en
Application filed by Chiron SRL filed Critical Chiron SRL
Publication of AU2001276619A1 publication Critical patent/AU2001276619A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The published genomic of Chlamydia pneumoniae reveals over 1000 putative encoded proteins but does not itself indicate which of these might to useful antigens for immunisation and vaccination or for diagnosis. This difficulty is addressed by the invention, which provides a number of C . pneumoniae protein sequences suitable for vaccine production and development and/or for diagnostic purposes.
AU2001276619A 2000-07-03 2001-07-03 Immunisation against chlamydia pneumoniae Abandoned AU2001276619A1 (en)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
GB0016363A GB0016363D0 (en) 2000-07-03 2000-07-03 Immunisation against chlamydia pneumoniae
GB0016363 2000-07-03
GB0017047A GB0017047D0 (en) 2000-07-11 2000-07-11 Immunisation against chlamydia pneumoniae
GB0017047 2000-07-11
GB0017983 2000-07-21
GB0017983A GB0017983D0 (en) 2000-07-21 2000-07-21 Immunisation against chlamydia pneumoniae
GB0019368A GB0019368D0 (en) 2000-08-07 2000-08-07 Immunisation against chlamydia pneumoniae
GB0019368 2000-08-07
GB0020440A GB0020440D0 (en) 2000-08-18 2000-08-18 Immunisation against chlamydia pneumoniae
GB0020440 2000-08-18
GB0022583 2000-09-14
GB0022583A GB0022583D0 (en) 2000-09-14 2000-09-14 Immunisation against chlamydia pneumoniae
GB0027549A GB0027549D0 (en) 2000-11-10 2000-11-10 Immunisation against chlamydia pneumoniae
GB0027549 2000-11-10
GB0031706A GB0031706D0 (en) 2000-12-22 2000-12-22 Immunisation against chlamydia pneumoniae
GB0031706 2000-12-22
PCT/IB2001/001445 WO2002002606A2 (en) 2000-07-03 2001-07-03 Immunisation against chlamydia pneumoniae

Publications (1)

Publication Number Publication Date
AU2001276619A1 true AU2001276619A1 (en) 2002-01-14

Family

ID=27571146

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001276619A Abandoned AU2001276619A1 (en) 2000-07-03 2001-07-03 Immunisation against chlamydia pneumoniae

Country Status (8)

Country Link
US (4) US20040005667A1 (en)
EP (2) EP1297005B1 (en)
JP (2) JP2004502415A (en)
AT (1) ATE440861T1 (en)
AU (1) AU2001276619A1 (en)
CA (1) CA2414884A1 (en)
DE (1) DE60139690D1 (en)
WO (1) WO2002002606A2 (en)

Families Citing this family (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7141244B1 (en) * 1992-03-02 2006-11-28 Chiron Srl Helicobacter pylori proteins useful for vaccines and diagnostics
GB2303854B (en) * 1994-07-01 1998-10-21 Rican Limited Helicobacter proteins and vaccines
PT909323E (en) * 1996-01-04 2007-06-04 Novartis Vaccines & Diagnostic Helicobacter pylori bacterioferritin
AU5365999A (en) 1998-08-20 2000-03-14 Connaught Laboratories Limited Nucleic acid molecules encoding pomp91a protein of (chlamydia)
WO2000011181A1 (en) 1998-08-20 2000-03-02 Connaught Laboratories Limited NUCLEIC ACID MOLECULES ENCODING INCLUSION MEMBRANE PROTEIN C OF $i(CHLAMYDIA)
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
US6649370B1 (en) 1998-10-28 2003-11-18 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6607730B1 (en) 1998-11-02 2003-08-19 Aventis Pasteur Limited/Aventis Pasteur Limitee Chlamydia antigens and corresponding DNA fragments and uses thereof
JP2002531093A (en) 1998-12-01 2002-09-24 アベンティス、パストゥール、リミテッド Chlamydia antigens and corresponding DNA fragments and uses thereof
US20020061848A1 (en) 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
KR20090088972A (en) 1998-12-08 2009-08-20 코릭사 코포레이션 Compositions for treating and diagnosing chlamydia infections, and pharmaceutical compositions and diagnostic kits comprising the same
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
US7297341B1 (en) 1998-12-23 2007-11-20 Sanofi Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
ATE384738T1 (en) 1998-12-28 2008-02-15 Aventis Pasteur CHLAMYDIA ANTIGENS, CORRESPONDING DNA FRAGMENTS AND THEIR USES
US6808713B1 (en) 1998-12-28 2004-10-26 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
GB9902555D0 (en) 1999-02-05 1999-03-24 Neutec Pharma Plc Medicament
WO2000055326A1 (en) 1999-03-12 2000-09-21 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
EP1177301B1 (en) 1999-05-03 2007-10-10 Sanofi Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
ATE384793T1 (en) 1999-09-20 2008-02-15 Aventis Pasteur CHLAMYDIA ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND THEIR USES
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
WO2001046224A2 (en) * 1999-12-22 2001-06-28 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
ES2391153T3 (en) 2000-02-28 2012-11-22 Novartis Vaccines And Diagnostics S.R.L. Heterologous expression of Neisseria proteins
US20020071831A1 (en) * 2000-04-04 2002-06-13 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
US20020132994A1 (en) * 2000-04-04 2002-09-19 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
AU2001255596A1 (en) 2000-04-21 2001-11-07 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
WO2001085972A2 (en) 2000-05-08 2001-11-15 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
JP2004502415A (en) 2000-07-03 2004-01-29 カイロン　エセ．ピー．アー． Immunization against Chlamydiapneumoniae
GB0024200D0 (en) * 2000-10-03 2000-11-15 Smithkline Beecham Sa Component vaccine
US20030059896A1 (en) * 2000-12-21 2003-03-27 Shire Biochem Inc. Novel chlamydia antigens and corresponding DNA fragments
US7082569B2 (en) 2001-01-17 2006-07-25 Outlooksoft Corporation Systems and methods providing dynamic spreadsheet functionality
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
ATE464317T1 (en) 2001-06-05 2010-04-15 Curevac Gmbh STABILIZED MRNA WITH INCREASED G/C CONTENT FOR GENE THERAPY
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
JP2005506322A (en) * 2001-08-31 2005-03-03 カイロン ソチエタ ア レスポンサビリタ リミタータ Helicobacter pylori vaccination
NZ533428A (en) 2001-12-12 2008-03-28 Chiron Srl Immunisation against chlamydia trachomatis
DE10162480A1 (en) 2001-12-19 2003-08-07 Ingmar Hoerr The application of mRNA for use as a therapeutic agent against tumor diseases
WO2003059381A2 (en) * 2002-01-18 2003-07-24 Curevac Gmbh Immunogenic preparations and vaccines on the basis of mrna
GB0203403D0 (en) 2002-02-13 2002-04-03 Chiron Spa Chlamydia cytotoxic-T cell epitopes
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
WO2004039399A1 (en) 2002-11-01 2004-05-13 Glaxosmithkline Biologicals S.A. Immunogenic composition
EP2279746B1 (en) 2002-11-15 2013-10-02 Novartis Vaccines and Diagnostics S.r.l. Surface proteins in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
US7893096B2 (en) 2003-03-28 2011-02-22 Novartis Vaccines And Diagnostics, Inc. Use of small molecule compounds for immunopotentiation
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
CA2528007C (en) 2003-06-02 2012-03-27 Chiron Corporation Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
CA2534502C (en) * 2003-08-19 2011-12-20 Shell Canada Limited Drilling system and method
AU2004291575A1 (en) * 2003-11-21 2005-06-02 Sanofi Pasteur Limited Immunization against Chlamydia infection
JP2007526318A (en) * 2004-03-02 2007-09-13 カイロン コーポレイション Immunogenic composition against Chlamydiapneumoniae
CA2571710A1 (en) 2004-06-24 2006-11-02 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
US20060165716A1 (en) 2004-07-29 2006-07-27 Telford John L Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
DE102004042546A1 (en) * 2004-09-02 2006-03-09 Curevac Gmbh Combination therapy for immune stimulation
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
GB0502096D0 (en) 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
WO2006089264A2 (en) 2005-02-18 2006-08-24 Novartis Vaccines And Diagnostics Inc. Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
CA2598488A1 (en) 2005-02-18 2006-08-31 Novartis Vaccines And Diagnostics, Inc. Immunogens from uropathogenic escherichia coli
WO2007047749A1 (en) 2005-10-18 2007-04-26 Novartis Vaccines And Diagnostics Inc. Mucosal and systemic immunizations with alphavirus replicon particles
US7527801B2 (en) 2005-11-22 2009-05-05 Novartis Vaccines And Diagnostics, Inc. Norovirus and Sapovirus antigens
US20090317421A1 (en) 2006-01-18 2009-12-24 Dominique Missiakas Compositions and methods related to staphylococcal bacterium proteins
ATE539079T1 (en) 2006-03-23 2012-01-15 Novartis Ag IMIDAZOCHINOXALINE COMPOUNDS AS IMMUNE MODULATORS
WO2007130629A1 (en) * 2006-05-05 2007-11-15 Perkinelmer Las, Inc Quantitative analysis of surface-derived samples using mass spectrometry
EP2586790A3 (en) 2006-08-16 2013-08-14 Novartis AG Immunogens from uropathogenic Escherichia coli
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
WO2009034473A2 (en) 2007-09-12 2009-03-19 Novartis Ag Gas57 mutant antigens and gas57 antibodies
PL2235046T3 (en) 2007-12-21 2012-12-31 Novartis Ag Mutant forms of streptolysin o
WO2009111337A1 (en) 2008-03-03 2009-09-11 Irm Llc Compounds and compositions as tlr activity modulators
NZ591768A (en) 2008-09-18 2012-11-30 Novartis Ag Vaccine adjuvant combinations
DK2349520T3 (en) 2008-10-27 2016-08-15 Glaxosmithkline Biologicals Sa Purification Procedure for Group A Streptococcus Carbohydrate
CN102307477B (en) 2009-01-05 2015-07-29 埃皮托吉尼西斯股份有限公司 Adjunvant composition and using method
CN103897045A (en) 2009-01-12 2014-07-02 诺华股份有限公司 Cna_b domain antigens in vaccines against gram positive bacteria
EP3549602A1 (en) 2009-03-06 2019-10-09 GlaxoSmithKline Biologicals S.A. Chlamydia antigens
ITMI20090946A1 (en) 2009-05-28 2010-11-29 Novartis Ag EXPRESSION OF RECOMBINANT PROTEINS
JP5867952B2 (en) 2009-06-10 2016-02-24 ノバルティス アーゲー Benzonaphthyridine-containing vaccine
EP2443250B8 (en) 2009-06-16 2016-09-21 GlaxoSmithKline Biologicals SA High-throughput complement-mediated antibody-dependent and opsonic bactericidal assays
NZ598459A (en) 2009-08-27 2014-03-28 Novartis Ag Adjuvant comprising aluminium, oligonucleotide and polycation
EA026401B1 (en) 2009-09-02 2017-04-28 Новартис Аг Immunogenic compositions including tlr activity modulators
JO3257B1 (en) 2009-09-02 2018-09-16 Novartis Ag Vehicles and installations as TLR
CA2779798C (en) 2009-09-30 2019-03-19 Novartis Ag Conjugation of staphylococcus aureus type 5 and type 8 capsular polysaccharides
RS56000B1 (en) 2009-10-30 2017-09-29 Glaxosmithkline Biologicals Sa Purification of staphylococcus aureus type 5 and type 8 capsular saccharides
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
AU2010339921B2 (en) 2009-12-15 2016-08-11 Glaxosmithkline Biologicals S.A. Homogeneous suspension of immunopotentiating compounds and uses thereof
AU2011232421B2 (en) 2010-03-23 2015-08-13 Novartis Ag Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc.
US9260762B2 (en) * 2010-04-16 2016-02-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Real time PCR assay for detection of bacterial respiratory pathogens
JP2013532008A (en) 2010-05-28 2013-08-15 テトリス オンライン インコーポレイテッド Interactive hybrid asynchronous computer game infrastructure
CA2804396C (en) 2010-07-06 2021-06-29 Novartis Ag Liposomes with lipids having an advantageous pka-value for rna delivery
ES2934240T3 (en) 2010-07-06 2023-02-20 Glaxosmithkline Biologicals Sa Virion-like delivery particles for self-replicating RNA molecules
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
PT2591114T (en) 2010-07-06 2016-08-02 Glaxosmithkline Biologicals Sa Immunisation of large mammals with low doses of rna
ES2646669T3 (en) 2010-07-06 2017-12-14 Glaxosmithkline Biologicals Sa Procedures for increasing an immune response by providing RNA
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
MX2013002332A (en) 2010-08-31 2013-03-18 Novartis Ag Lipids suitable for liposomal delivery of protein-coding rna.
HRP20230185T8 (en) 2010-08-31 2023-07-21 Glaxosmithkline Biologicals Sa Pegylated liposomes for delivery of immunogen-encoding rna
US20120177681A1 (en) 2010-09-01 2012-07-12 Manmohan Singh Formulation of immunopotentiators
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
HRP20220796T1 (en) 2010-10-01 2022-10-14 ModernaTX, Inc. Ribonucleic acids containing n1-methyl-pseudouracils and uses thereof
KR102162111B1 (en) 2010-10-11 2020-10-07 노파르티스 아게 Antigen delivery platforms
WO2012082914A1 (en) 2010-12-14 2012-06-21 Novartis Ag Flow cytometry analysis of materials adsorbed to metal salts
CA2860331A1 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
ES2612511T3 (en) 2011-01-27 2017-05-17 Glaxosmithkline Biologicals Sa Adjuvant nanoemulsions with crystallization inhibitors
CA2828844C (en) 2011-03-02 2020-07-14 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
ES2785108T3 (en) 2011-03-24 2020-10-05 Glaxosmithkline Biologicals Sa Adjuvant nanoemulsions with phospholipids
DE12722942T1 (en) 2011-03-31 2021-09-30 Modernatx, Inc. RELEASE AND FORMULATION OF MANIPULATED NUCLEIC ACIDS
IL313030A (en) 2011-05-17 2024-07-01 Univ Rockefeller Human immunodeficiency virus neutralizing antibodies and methods of use thereof
BR112013032410A2 (en) * 2011-06-24 2017-01-17 Epitogenesis Inc pharmaceutical compositions comprising a combination of selection vehicles, vitamins, tannins and flavonoids as antigen specific immunomodulators
US20140141070A1 (en) 2011-07-06 2014-05-22 Andrew Geall Liposomes having useful n:p ratio for delivery of rna molecules
EP3332802A1 (en) 2011-07-06 2018-06-13 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
WO2013033563A1 (en) 2011-08-31 2013-03-07 Novartis Ag Pegylated liposomes for delivery of immunogen-encoding rna
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2755683B1 (en) 2011-09-14 2019-04-03 GlaxoSmithKline Biologicals SA Methods for making saccharide-protein glycoconjugates
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
CN104080479B (en) 2011-11-07 2019-11-05 葛兰素史密丝克莱恩生物有限公司 Carrier molecules including spr0096 and spr2021 antigen
SG11201402666WA (en) 2011-12-16 2014-10-30 Moderna Therapeutics Inc Modified nucleoside, nucleotide, and nucleic acid compositions
CN104519910B (en) 2012-03-07 2017-05-03 诺华股份有限公司 Adjuvanted formulations of streptococcus pneumoniae antigens
SI2822947T1 (en) 2012-03-07 2016-10-28 Glaxosmithkline Biologicals S.A. Arginine salts of a tlr7 agonist
MX372965B (en) 2012-03-08 2020-04-01 Glaxosmithkline Biologicals Sa ADJUVATED FORMULATIONS OF DIPHTHERIA, TETANUS AND PERTUSSUS (DTP) BOOSTER VACCINES.
CA2868434A1 (en) 2012-04-02 2013-10-10 Moderna Therapeutics, Inc. Modified polynucleotides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
CN104736180A (en) 2012-05-22 2015-06-24 诺华股份有限公司 Meningococcus serogroup X conjugate
EP2897635A1 (en) 2012-09-18 2015-07-29 Novartis AG Outer membrane vesicles
WO2014081507A1 (en) 2012-11-26 2014-05-30 Moderna Therapeutics, Inc. Terminally modified rna
CA2899787A1 (en) 2013-02-01 2014-08-07 Glaxosmithkline Biologicals Sa Intradermal delivery of immunological compositions comprising toll-like receptor agonists
WO2014136086A1 (en) 2013-03-08 2014-09-12 Novartis Ag Lipids and lipid compositions for the delivery of active agents
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
CN105980401A (en) 2013-10-03 2016-09-28 现代治疗公司 Polynucleotides encoding low density lipoprotein receptor
CA2925021A1 (en) 2013-11-01 2015-05-07 Curevac Ag Modified rna with decreased immunostimulatory properties
EP3083579B1 (en) 2013-12-19 2022-01-26 Novartis AG Lipids and lipid compositions for the delivery of active agents
PL3083556T3 (en) 2013-12-19 2020-06-29 Novartis Ag Lipids and lipid compositions for the delivery of active agents
US10342761B2 (en) 2014-07-16 2019-07-09 Novartis Ag Method of encapsulating a nucleic acid in a lipid nanoparticle host
EP3188760B1 (en) 2014-09-05 2023-12-06 Novartis AG Lipids and lipid compositions for the delivery of active agents
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
EP3324979B1 (en) 2015-07-21 2022-10-12 ModernaTX, Inc. Infectious disease vaccines
EP3364950A4 (en) 2015-10-22 2019-10-23 ModernaTX, Inc. VACCINES AGAINST TROPICAL DISEASES
US10835601B2 (en) * 2015-11-10 2020-11-17 Ohio State Innovation Foundation Methods and compositions related to accelerated humoral affinity
US11612664B2 (en) 2016-04-05 2023-03-28 Gsk Vaccines S.R.L. Immunogenic compositions
EP3681514A4 (en) 2017-09-14 2021-07-14 ModernaTX, Inc. Zika virus rna vaccines
BR112020016314A2 (en) 2018-02-12 2020-12-15 Inimmune Corporation PHARMACEUTICALLY ACCEPTABLE COMPOUNDS OR SALTS, PHARMACEUTICAL COMPOSITION, KIT, AND, METHODS FOR ELICITATING, INTENSIFYING OR MODIFYING AN IMMUNOLOGICAL RESPONSE, TO TREAT, PREVENT OR REDUCE THE SUSCETIBILITY TO CANCER, TO REDUCE, UNDERSTAND TREAT, PREVENT OR REDUCE SUSCEPTIBILITY TO AN ALLERGY, TO TREAT, PREVENT OR REDUCE SUSCETIBILITY TO AUTOIMMUNE AFFECTION, TO TREAT, PREVENT OR REDUCE SUSCETIBILITY IN A SUBJECT TO BACTERIAL INFECTION, ALTERNATE, VENEER, NAVAL, NAVARI TREAT, PREVENT OR REDUCE SUSCEPTIBILITY TO AUTOIMMUNITY, ALLERGY, ISCHEMIA OR SEPSIS REPERFUSION, TO TREAT, PREVENT OR REDUCE THE GRAVITY OF EPILETIC ATTACKS AND TO TREAT, PREVENT OR REDUCE THE MACANTIC HERITAGE OF HERITAGE,
EP3938379A4 (en) 2019-03-15 2023-02-22 ModernaTX, Inc. HIV RNA VACCINE
KR20230117105A (en) 2020-11-04 2023-08-07 엘리고 바이오사이언스 Cutibacterium acnes recombinant phage, manufacturing method and use thereof
EP4387597A1 (en) 2021-08-16 2024-06-26 GlaxoSmithKline Biologicals SA Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof
US20250134824A1 (en) 2021-08-16 2025-05-01 Glaxosmithkline Biologicals Sa Low-dose lyophilized rna vaccines and methods for preparing and using the same
GB202303019D0 (en) 2023-03-01 2023-04-12 Glaxosmithkline Biologicals Sa Method of lyophilisation
GB202311382D0 (en) 2023-07-25 2023-09-06 Glaxosmithkline Biologicals Sa Lyophilised compostion

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869608A (en) * 1989-03-17 1999-02-09 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and amino acid sequences of the four variable domains of the major outer membrane proteins of Chlamydia trachomatis
CA2294651A1 (en) * 1997-06-23 1998-12-30 Svend Birkelund Surface exposed proteins from chlamydia pneumoniae
ES2352082T3 (en) * 1997-11-21 2011-02-15 Merck Serono Biodevelopment POLLIPEPTIDE OF THE EXTERNAL MEMBRANE OF CHLAMYDIA PNEUMONIAE, FRAGMENTS OF THE SAME AND ITS USES, IN PARTICULAR FOR THE DIAGNOSIS, THE PREVENTION AND TREATMENT OF AN EXTENSIVE MEMBERSHIP OF THE EXTERNAL MEMBRANE OF CHLAMYDIA MUSIC FOR THE PNEUMONIC PARISULOSIS IN THE PNEUMONTIC PARTICULARM DIAGNOSIS, PREVENTION AND TREATMENT OF AN INFECTION.
KR20010032336A (en) * 1997-11-21 2001-04-16 브랑디 빠스깔 Chlamydia pneumoniae genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
KR100769103B1 (en) 1997-11-28 2007-10-23 세로노 제네틱스 인스티튜트 에스.에이. Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
WO2000027994A2 (en) 1998-11-12 2000-05-18 The Regents Of The University Of California Chlamydia pneumoniae genome sequence
US6822071B1 (en) * 1998-11-12 2004-11-23 The Regents Of The University Of California Polypeptides from Chlamydia pneumoniae and their use in the diagnosis, prevention and treatment of disease
US6565856B1 (en) 1998-12-08 2003-05-20 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
KR20090088972A (en) * 1998-12-08 2009-08-20 코릭사 코포레이션 Compositions for treating and diagnosing chlamydia infections, and pharmaceutical compositions and diagnostic kits comprising the same
US20020061848A1 (en) 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
GB9902555D0 (en) 1999-02-05 1999-03-24 Neutec Pharma Plc Medicament
EP1177301B1 (en) 1999-05-03 2007-10-10 Sanofi Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
ATE384793T1 (en) 1999-09-20 2008-02-15 Aventis Pasteur CHLAMYDIA ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND THEIR USES
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
WO2001046224A2 (en) 1999-12-22 2001-06-28 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
US20020132994A1 (en) * 2000-04-04 2002-09-19 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
AU2001255596A1 (en) 2000-04-21 2001-11-07 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
WO2001085972A2 (en) 2000-05-08 2001-11-15 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
JP2004502415A (en) 2000-07-03 2004-01-29 カイロン　エセ．ピー．アー． Immunization against Chlamydiapneumoniae

Also Published As

Publication number Publication date
US20040005667A1 (en) 2004-01-08
EP1297005A2 (en) 2003-04-02
ATE440861T1 (en) 2009-09-15
EP2166019A2 (en) 2010-03-24
CA2414884A1 (en) 2002-01-10
US20070116726A1 (en) 2007-05-24
WO2002002606A3 (en) 2002-06-06
WO2002002606A2 (en) 2002-01-10
DE60139690D1 (en) 2009-10-08
EP2166019A3 (en) 2010-06-09
JP2012147798A (en) 2012-08-09
JP2004502415A (en) 2004-01-29
US20100056447A1 (en) 2010-03-04
EP1297005B1 (en) 2009-08-26
US20120171236A1 (en) 2012-07-05

Similar Documents

Publication Publication Date Title
AU2001276619A1 (en) Immunisation against chlamydia pneumoniae
WO2003049762A3 (en) Immunisation against chlamydia trachomatis
EP1144998A3 (en) Neisseria genomic sequences and methods of their use
WO2001031019A3 (en) Neisserial antigenic peptides
NO976119L (en) OMP26 antigen from Haemophilus influenzae
WO2000039299A3 (en) Streptococcus antigens
EP1935991A3 (en) Nucleic acid vaccines for prevention of flavivirus infection
EP1731166A3 (en) Streptococcus pneumoniae proteins and vaccines
ATE375391T1 (en) CHLAMYDIA ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND THEIR USES
WO2000005378A3 (en) Streptococcus suis vaccines and diagnostic tests
ITFI920052A1 (en) PROTEIN EXTRACTED FROM HELICOBACTER PYLORI CYTOTOXIC STRAINS, GENE THAT EXPRESSES IT, USE OF PROTEIN AS VACCINE OR DIAGNOSTIC.
EP1586646A3 (en) Lawsonia intracellularis vaccine
ATE120487T1 (en) THERAPEUTIC COMPOSITIONS AGAINST STREPTOCOCCAL INFECTIONS, TRANSFORMED HOSTS, METHODS OF IMMUNIZATION AND GENETICALLY PRODUCED PRODUCTS.
EP1220925B8 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
CA2294701A1 (en) Surface antigens and proteins useful in compositions for the diagnosis and prevention of lyme disease
WO2004020609A3 (en) Streptococcus pneumoniae antigens for diagnosis, treatment and prevention of active infection
EP2172214A3 (en) Chlamydia antigens and corresponding DNA fragments and uses thereof
EP2088197A3 (en) Haemophilus influenzae antigens and corresponding DNA fragments
WO2000044392A3 (en) Identification of specific differentially expressed mycobacterial antigens
EP1020516A3 (en) Leptospira vaccine antigens for the prevention of leptospirosis
Kunkle Molecular cloning and characterization of a unique 21-kilodalton antigen of Serpulina hyodysenteriae.
TH44467A (en) Campylobacter vaccine
WO2000046242A3 (en) 19 KILODALTON PROTEIN OF $i(HELICOBACTER PYLORI)